Artificial Organs Биоинженерия

Design and Simulation of an AI ‐Powered Artificial Pancreas System With Personalized Glucose Sensing and Insulin Delivery

G. Kalyani, T. Pratap, Sateesh Jasti
Wiley · 2026-11-13 · DOI 10.1111/aor.70278

Аннотация

ABSTRACT Background Achieving tight glycemic control in Type 1 diabetes is challenged by non‐linear metabolic dynamics and insulin‐stacking risk. Artificial intelligence models offer improved personalization, but their opacity raises safety concerns, particularly for basal insulin dosing, which is often treated as static in existing decision‐support systems. Methods We propose a hybrid closed‐loop system combining a data‐driven LightGBM regressor for basal dose prediction, trained on the T1D‐UOM dataset, with a physiologically grounded, rule‐based safety layer at the edge. Basal insulin is predicted from cyclical time encoding and glucose rate‐of‐change; bolus dosing follows carbohydrate intake and correction requirements. A time‐bounded insulin‐on‐board model, an uncertainty‐adaptive post‐bolus damping factor, and a predictive low‐glucose‐suspend rule reproducing the Tandem Basal‐IQ protocol together suspend or reduce delivery when residual insulin is high or hypoglycemia is projected. The system was evaluated in silico over 60 continuous days under shadow‐mode replay and closed‐loop reduced‐order simulation, including an ablation with bolus delivery suppressed. Results Under chronological, within‐subject validation, the offline basal estimator achieved and U; under strict leave‐one‐subject‐out validation on the same real cohort, performance did not generalize to unseen subjects (, U). The hybrid controller maintained Time‐in‐Range at 62.8% within the reduced‐order closed‐loop simulation, with no violations of the insulin‐on‐board suspension or damping rules; suppressing bolus delivery in an ablation within this simulation dropped Time‐in‐Range to 26.1%, indicating that, within the reduced‐order model, bolus delivery is a determinant of simulated glycemic outcome. Conclusions The proposed architecture demonstrates a safety‐audited template for combining machine‐learning basal prediction with clinically grounded dosing rules. Validation on real outcome data and physical hardware is identified as the next steps toward clinical translation.

Читать у издателя →